Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > T2 Biosystems Raises $10.8 Million in Series B Financing: Industry Leader Stan Lapidus Joins Board of Directors

Abstract:
T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced that it has raised $10.8 million in a Series B financing. Proceeds from the financing will be used to accelerate the development of T2 Biosystems' revolutionary rapid diagnostic platform.

T2 Biosystems Raises $10.8 Million in Series B Financing: Industry Leader Stan Lapidus Joins Board of Directors

Cambridge, MA | Posted on October 17th, 2008

The company's initial investors, Flagship Ventures, Polaris Venture Partners and Flybridge Capital Partners were joined by new investors Partners Healthcare and In-Q-Tel in the round. T2 Biosystems previously closed a $5.5 million Series A financing in 2006.

"We are excited about the growing recognition of the value of our unique, miniaturized diagnostic platform and that we are attracting financial commitment from investors of this caliber underscores the significant progress of our team over the past two years," said John McDonough, CEO of T2 Biosystems. "Our mission is to revolutionize medical diagnostics and dramatically improve patient care by enabling immediate, accurate testing for almost any health condition, in nearly any setting and this funding allows us to continue to develop our initial panel of diagnostic tests and continue to advance our instrument development through beta testing."

The company also announced the addition of Stanley N. Lapidus to the Company's Board of Directors. Mr. Lapidus is an experienced life-science entrepreneur, having founded three highly successful life science diagnostic start-ups including Cytyc Corporation.

"We are honored to have Stan join our board as he has been an instrumental and legendary figure in the diagnostics industry for more than two decades," said McDonough. "Stan is joining our board at a very exciting time at T2, and the combination of his scientific knowledge and business acumen will serve us well as we continue to grow the business."

"The breakthrough field of miniaturized MR technology represents an entirely new approach for developing highly efficient and portable diagnostics, and T2 Biosystems has all the necessary components to establish a dominant position in the space," said Mr. Lapidus. "T2's progress to date has been extremely impressive and I am looking forward to working with the outstanding team in place to help bring this revolutionary technology to the marketplace."

T2 Biosystems is developing the next generation of medical diagnostic products through its proprietary technology, which combines nanotechnology and the miniaturization of proven MR technology to develop rapid, accurate and portable diagnostics. T2 Biosystems' technology has been validated in multiple published journal articles and has shown to accurately analyze viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The Company is developing a pipeline of diagnostic products based on its technology, including devices for hospitals, diagnostic laboratories and medical offices, as well as individual patients.

####

About T2 Biosystems, Inc.
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MRI) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Yates Public Relations
Adriana Jenkins
617-744-1713

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Researchers discover new chemical sensing technique: Technique allows sharper detail -- and more information -- with near infrared light June 24th, 2016

GraphExeter illuminates bright new future for flexible lighting devices June 23rd, 2016

Imaging

Researchers discover new chemical sensing technique: Technique allows sharper detail -- and more information -- with near infrared light June 24th, 2016

Coexistence of superconductivity and charge density waves observed June 23rd, 2016

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

NanoLabNL boosts quality of research facilities as Dutch Toekomstfonds invests firmly June 10th, 2016

Oxford Nanoimaging to provide desktop super-resolution microscopes May 10th, 2016

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

Philadelphia Mathematician Robert Clark Turns to Crowdfunding to Support Nanotechnology Research That Could Lead to ‘Flying’ Cars and Space Elevator April 4th, 2016

Nanomedicine

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Self-assembling icosahedral protein designed: Self-assembling icosahedral protein designed June 22nd, 2016

Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016

New nanoparticle technology developed to treat aggressive thyroid cancer: Platform designed to deliver nanotherapy effective in preclinical models of metastatic anaplastic thyroid cancer June 21st, 2016

Announcements

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Researchers discover new chemical sensing technique: Technique allows sharper detail -- and more information -- with near infrared light June 24th, 2016

GraphExeter illuminates bright new future for flexible lighting devices June 23rd, 2016

Soft decoupling of organic molecules on metal June 23rd, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

George Clark Named Chief Financial Officer and Associate Laboratory Director for Business Services at Brookhaven Lab February 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic